Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Merck
Medtronic
AstraZeneca
Harvard Business School
Johnson and Johnson

Last Updated: January 29, 2022

DrugPatentWatch Database Preview

Claims for Patent: 6,656,918

➤ Subscribe for complete access

« Back to Dashboard

Summary for Patent: 6,656,918
Title: Prophylactic and therapeutic treatment of the ductal epithelium of a mammary gland for cancer
Abstract:The present invention provides prophylactic and therapeutic methods of treating the ductal epithelium of an exocrine gland, in particular a mammary gland, for disease, in particular cancer. The methods comprise contacting the ductal epithelium of the exocrine gland with an epithelium-destroying gent, preferably by ductal cannulation, so as to realize a prophylactic or therapeutic effect.
Inventor(s): Sukumar; Saraswati Vaidyanathan (Columbia, MD)
Assignee: Johns Hopkins University School of Medicine (Baltimore, MD)
Application Number:09/746,588
Patent Claims:1. A method of treating the ductal epithelium of a mammary gland prophylactically for cancer, which method consists essentially of contacting the ductal epithelium of the mammary gland by ductal cannulation with a cytotoxic agent to inhibit the formation of cancer of ductal epithelial origin.

2. A method of treating the ductal epithelium of a mammary gland prophylactically for cancer, which method consists essentially of contacting, by ductal cannulation, the ductal epithelium of the mammary gland with a cytotoxic agent, wherein said cytotoxic agent is selected from the group consisting of genistein, okadaic acid, 1-.beta.-D-arabinofuranosyl-cytosine, arabinofuranosyl-5-aza-cytosine, cisplatin, carboplatin, actinomycin D, asparaginase, bis-chloro-ethyl-nitroso-urea, bleomycin, chlorambucil, cyclohexyl-chloro-ethyl-nitroso-urea, cytosine arabinoside, duanomycin, etoposide, hydroxyurea, melphalan, mercaptopurine, mitomycin C, nitrogen mustard, procarbazine, teniposide, thioguanine, thiotepa, vincristine, 5-fluorouracil, 5-fluorocytosine, adriamycin, cyclophosphamide, methotrexate, vinbiastine, doxorubicin, leucovorin, taxol, an anti-estrogen agent, an intracellular antibody against an oncogene, a flavonol, Guan-mu-tong extract, a retinoid, an analogue of a retinoid, and a monoterpene so as to inhibit the formation of cancer of ductal epithelial origin.

3. The method of claim 2, which additionally comprises contracting the ductal epithelium with a cytokine or hematopoietic growth factor.

4. The method of claim 3, wherein said hematopoietic growth factor is granulocyte macrophage-colony stimulating factor (GM-CSF).

5. The method of claim 1, wherein said mammary gland has been treated therapeutically with surgical removal of the cancerous tissue, radiation therapy, and/or chemotherapy, and the ductal epithelium of the mammary gland is contacted, either concomitantly or subsequently, with the cytotoxic agent so as to destroy any remaining cancerous cells as well as noncancerous cells and inhibit the spread of cancer.

6. The method of claim 5, which additionally comprises contacting the ductal epithelium with a cytokine or hematopoietic growth factor.

7. The method of claim 6, wherein said hematopoietic growth factor is GM-CSF.

8. The method of claim 2, wherein said mammary gland has been treated therapeutically with surgical removal of the cancerous tissue, radiation therapy, and/or chemotherapy, and the ductal epithelium of the mammary gland is contacted, either concomitantly or subsequently, with the cytotoxic agent so as to destroy any remaining cancerous cells as well as noncancerous cells and inhibit the spread of cancer.

9. The method of claim 8, which additionally comprises contacting the ductal epithelium with a cytokine or hematopoietic growth factor.

10. The method of claim 9, wherein said hematopoietic growth factor is GM-CSF.

11. The method of claim 1, wherein said cytotoxic agent is selected from the group consisting of genistein, okadaic acid; 1-.beta.-D-arabinofuranosyl-cytosine, arabinofuranosyl-5-aza-cytosine, cisplatin, carboplatin, actinomycin D, asparaginase, bis-chloro-ethyl-nitroso-urea, bleomycin, chlorambucil, cyclohexyl-chloro-ethyl-nitroso-urea, cytosine arabinoside, duanomycin, etoposide, hydroxyurea, melphalan, mercaptopurine, mitomycin C, nitrogen mustard, procarbazine, teniposide, thioguanine, thiotepa, vincristine, 5-fluorouracil, 5-fluorocytosine, adriamycin, cyclophosphamide, methotrexate, vinbiastine, doxorubicin, leucovorin, taxol, an anti-estrogen agent an intracellular antibody against an oncogene, a flavonol, Guan-mu-tong extract, a retinoid, an analogue of a retinoid, and a monoterpene.

12. The method of claim 11, wherein said anti-estrogen agent is tamoxifen.

13. The method of claim 2, wherein said cytotoxic agent is selected from the group consisting of genistein, okadaic acid, 1-.beta.-D-arabinofuranosyl-cytosine, arabinofuranosyl-5-aza-cytosine, cisplatin, carboplatin, actinomycin D, asparaginase, bis-chloro-ethyl-nitroso-urea, bleomycin, chlorambucil, cyclohexyl-chloro-ethyl-nitroso-urea, cytosine arabinoside, duanomycin, etoposide, hydroxyurea, melphalan, mercaptopurine, mitomycin C, nitrogen mustard, procarbazine, teniposide, thioguanine, thiotepa, vincristine, 5-fluorouracil, 5-fluorocytosine, adriamycin, cyclophosphamide, methotrexate, vinblastine, Image Page 7 doxorubicin, leucovorin, taxol, an anti-estrogen agent, an intracellular antibody against an oncogene, a flavonol, Guan-mu-tong extract, a retinoid, an analogue of a retinoid, and a monoterpene.

14. The method of claim 13, wherein said anti-estrogen agent is tamoxifen.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Boehringer Ingelheim
Colorcon
McKesson
Harvard Business School
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.